Cytokinetics, Inc.

Smithkline Beecham Corporation

Astellas Pharma Gmbh

Amgen Inc.

Pu-Ping Lu

Bradley Paul Morgan

David John Morgans, Jr

Alex R Muci

Xiangping Qian

Erica Anne Kraynack

Todd Tochimoto

Scott E Collibee

Jeffrey Warrington

Gustave Bergnes

Chihyuan Chuang

Luke W Ashcraft

Zhe Yang

Fady Malik

Chihyuan (Grace) Chuang

Antonio Romero

Jeffrey T Finer

Susumu Yamaki

Kathleen Ann Elias

Whitney Walter Smith

Bing Yao

Wenyue Wang

Marc Andrew Garard

Adam Lewis Tomasi

Hiroaki Tanaka

Takashi Kamikubo

Masanori Miura

Tomoyuki Saito

Ippei Sato

Yuji Matsushima

Yasuhiro Shiina

Kayoko Mihara

Munemichi Ohe

Hiroshi Kiyohara

Steven David Knight

Dashyant Dhanak

Bainian Feng

Jeff Gardina

Alan James Russell

Qing (Kevin) Lu

Kazuyuki Tsuchiya

Ikumi Kuriwaki

Takuya Makino

Toshio Kurosaki

Eriko Honjo

Ryuichi Sekioka

Naoto Katoh

Yuka Koizumi

Makoto Yamasaki

Andrew I McDonald

David Morgans

Chris Evans

William F Browne, Iv

Todd c/o Cytokynetics Inc Tochimoto

Alex c/o Cytokinetics Inc Muci

David J Morgans

Jeffrey Michael Warrington

Scott Emile Collibee

Provided herein are compounds of formula (I): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X, X, R, R, R, R, R, and Rare as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Bicyclic 1,4-diazepanones and therapeutic uses thereof

Certain substituted urea derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

Compounds, compositions and methods

Provided herein are compounds of formula (1): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, wherein X, X, R, R, R, R, R, and Rare as defined herein. Also provided herein is a pharmaceutically acceptable composition comprising a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided herein are methods of using a compound of formula (I), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, to treat various diseases, disorders, and conditions responsive to the modulation of the contractility of the skeletal sarcomere.

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Tetrahydroisoquinoline derivatives

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Amino-pyrimidine skeletal muscle modulators

Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, R, R, R, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

Substituted pyridazines as skeletal muscle modulators

Growing community of inventors

Foster City, CA, United States of America

Pu-Ping Lu